Case Control Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 670-686
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.670
Expression and significance of pigment epithelium-derived factor and vascular endothelial growth factor in colorectal adenoma and cancer
Ye Yang, Wu Wen, Feng-Lin Chen, Ying-Jie Zhang, Xiao-Cong Liu, Xiao-Yan Yang, Shan-Shan Hu, Ye Jiang, Jing Yuan
Ye Yang, Digestive Diseases, Chengdu Qingbaijiang District People's Hospital, Chengdu 610300, Sichuan Province, China
Wu Wen, Ying-Jie Zhang, Xiao-Cong Liu, Xiao-Yan Yang, Shan-Shan Hu, Ye Jiang, Jing Yuan, Digestive Diseases, Chengdu Second People’s Hospital, Chengdu 610000, Sichuan Province, China
Feng-Lin Chen, Graduate School, Chengdu Medical College, Chengdu 610000, Sichuan Province, China
Author contributions: Wen W proposed and designed the project, provided scientific research funds, and coordinated and contacted various matters related to the pathology department; Zhang YJ, Liu XC and Yang XY collected the pathological specimens; Hu SS, Jiang Y and Yuan J performed the collection of patient data and summarized the experimental data; Yang Y did most of the experiments and wrote the first draft of the paper; Chen FL performed the statistical analysis of the data; all authors read, revised, and agreed to the final manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of the Second People's Hospital of Chengdu.
Informed consent statement: All patients gave informed consent.
Conflict-of-interest statement: The authors declare no competing interests.
Data sharing statement: The data that support the findings of this study are available on request from the corresponding author, upon reasonable request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wu Wen, Doctor, Chief Physician, Digestive Diseases, Chengdu Second People’s Hospital, No. 10 Qingyunan Street, Jinjiang District, Chengdu 610000, Sichuan Province, China. wenwu2@qq.com
Received: November 7, 2023
Peer-review started: November 7, 2023
First decision: December 31, 2023
Revised: January 16, 2024
Accepted: February 4, 2024
Article in press: February 4, 2024
Published online: March 15, 2024
Core Tip

Core Tip: Targeted therapy is one of the most widely recognized and accepted methods for the treatment of colorectal cancer (CRC). Recent years have brought an intense focus to the study of the angiogenic signaling pathway, there have been studies showing that the infiltration, staging, and metastasis of colorectal are related to pigment epithelium-derived factors (PEDF) and vascular endothelial growth factors, but the current domestic and foreign studies on PEDF almost do not involve colorectal adenoma, a precancerous lesion. In our study, colorectal adenoma, a precancerous lesion, was added to analyze and explore the possibility of PEDF as a new target for early prevention and later treatment of CRC.